Dosage of Ciprofloxacin 0.3% Thephaco in details
Ciprofloxacin 0.3% Thephaco XR and Ciprofloxacin 0.3% Thephaco immediate-release tablets are not interchangeable. Ciprofloxacin 0.3% Thephaco XR should be administered orally once daily (Table 1).
Patients whose therapy is started with Ciprofloxacin 0.3% Thephaco IV for UTIs may be switched to Ciprofloxacin 0.3% Thephaco XR when clinically indicated at the discretion of the physician.
- Ciprofloxacin 0.3% Thephaco XR tablets should be taken whole and not split, crushed, or chewed.
- Ciprofloxacin 0.3% Thephaco XR should be administered at least 2 hours before or 6 hours after antacids containing magnesium or aluminum, polymeric phosphate binders (for example, sevelamer, lanthanum carbonate), as well as sucralfate, VIDEX® (didanosine) chewable/buffered tablets or pediatric powder, other highly buffered drugs, metal cations such as iron, and multivitamin preparations with zinc.
- Concomitant administration of Ciprofloxacin 0.3% Thephaco XR with dairy products (like milk or yogurt) or with calcium-fortified products alone should be avoided since decreased absorption is possible. A 2-hour window between substantial calcium intake (greater than 800 mg) and dosing with Ciprofloxacin 0.3% Thephaco XR is recommended.
Adequate hydration of patients receiving Ciprofloxacin 0.3% Thephaco XR should be maintained to prevent the formation of highly concentrated urine. Crystalluria has been reported with quinolones.
Impaired Renal Function
- In patients with cUTI and acute uncomplicated pyelonephritis with a creatinine clearance of ≤ 30 mL/min, the dose of Ciprofloxacin 0.3% Thephaco XR should be reduced from 1000 mg to 500 mg daily. The use of Ciprofloxacin 0.3% Thephaco 1000 mg XR tablets is not recommended in this patient population.
- For patients on hemodialysis or peritoneal dialysis, administer Ciprofloxacin 0.3% Thephaco XR after the dialysis procedure is completed (maximum dose should be Ciprofloxacin 0.3% Thephaco 500 mg XR every 24 hours). The use of Ciprofloxacin 0.3% Thephaco 1000 mg XR is not recommended in this patient population.
- For patients on continuous ambulatory peritoneal dialysis (CAPD), the maximum dose should be 500 mg every 24 hours.
What other drugs will affect Ciprofloxacin 0.3% Thephaco?
Tell your doctor about all medicines you use, and those you start or stop using during your treatment with Ciprofloxacin 0.3% Thephaco, especially:
glyburide, methotrexate, metoclopramide, phenytoin, probenecid, theophylline;
a blood thinner (warfarin, Coumadin, Jantoven);
a diuretic or "water pill";
heart rhythm medication--amiodarone, disopyramide, dofetilide, dronedarone, procainamide, quinidine, sotalol, and others;
medicine to treat depression or mental illness--amitriptylline, clomipramine, desipramine, iloperidone, imipramine, nortriptyline, thioridazine, ziprasidone, and others; or
NSAIDs (nonsteroidal anti-inflammatory drugs)--aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), celecoxib, diclofenac, indomethacin, meloxicam, and others.
This list is not complete. Other drugs may interact with Ciprofloxacin 0.3% Thephaco, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.
Ciprofloxacin 0.3% Thephaco interactions
Some quinolones, including Ciprofloxacin 0.3% Thephaco, have also been shown to interfere with the metabolism of caffeine. This may lead to reduced clearance of caffeine and a prolongation of its serum half-life.
Some quinolones, including Ciprofloxacin 0.3% Thephaco, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
The concomitant administration of Ciprofloxacin 0.3% Thephaco with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.
Histamine H2-receptor antagonists
Histamine H2-receptor antagonists appear to have no significant effect on the bioavailability of Ciprofloxacin 0.3% Thephaco.
Renal tubular transport of methotrexate may be inhibited by concomitant administration of Ciprofloxacin 0.3% Thephaco, potentially leading to increased plasma levels of methotrexate. This might increase the risk of methotrexate toxic reactions. Therefore, patients under methotrexate therapy should be carefully monitored when concomitant Ciprofloxacin 0.3% Thephaco therapy is indicated.
Multivalent Cation-Containing Products
Concurrent administration of a quinolone, including Ciprofloxacin 0.3% Thephaco, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of Ciprofloxacin 0.3% Thephaco, resulting in serum and urine levels considerably lower than desired. Proquin XR should be administered at least 4 hours before or 2 hours after these products. This time window is different than for other oral formulations of Ciprofloxacin 0.3% Thephaco, which are usually administered 2 hours before or 6 hours after antacids.
Non-steroidal anti-inflammatory drugs (but not aspirin)
These drugs in combination with very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies.
The rate and extent of absorption of Ciprofloxacin 0.3% Thephaco was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion. Omeprazole should be taken as directed and Proquin XR should be taken with a main meal of the day, preferably the evening meal..
Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant Ciprofloxacin 0.3% Thephaco.
Probenecid interferes with renal tubular secretion of Ciprofloxacin 0.3% Thephaco and produces an increase in the level of Ciprofloxacin 0.3% Thephaco in serum.
As with some other quinolones, concurrent administration of Ciprofloxacin 0.3% Thephaco with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life. This may result in increased risk of theophylline-related adverse reactions. If concomitant use cannot be avoided, serum levels of theophylline should be monitored and dosage adjustments made as appropriate.
Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives. When these products are administered concomitantly, prothrombin time or other suitable coagulation tests should be monitored.
- DailyMed. "CIPROFLOXACIN; DEXAMETHASONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailymed/se... (accessed September 17, 2018).
- Wikipedia. "ciprofloxacin: Link to the compound information in Wikipedia.". https://en.wikipedia.org/wiki/Ciprofloxa... (accessed September 17, 2018).
- MeSH. "Topoisomerase II Inhibitors". https://www.ncbi.nlm.nih.gov/mesh/680590... (accessed September 17, 2018).
- ChEBI. "ChEBI Ontology: The ChEBI Ontology is a structured classification of the entities contained within ChEBI.". http://www.ebi.ac.uk/chebi/userManualFor... (accessed September 17, 2018).
- PubMed Health. "Ciprofloxacin (Into the eye) (Ciloxan): This section provide the link out information of drugs collectetd in PubMed Health. ". http://www.ncbi.nlm.nih.gov/pubmedhealth... (accessed September 17, 2018).
- WIPO. "International Patent Classification: The World Intellectual Property Organization (WIPO) International Patent Classification (IPC), established by the Strasbourg Agreement 1971, provides for a hierarchical system of language independent symbols for the classification of patents and utility models according to the different areas of technology to which they pertain.". http://www.wipo.int/classifications/ipc/ (accessed September 17, 2018).
- ChemIDplus. "ChemIDplus Chemical Information Classification: ChemIDplus is a TOXNET (TOXicology Data NETwork) databases that contain chemicals and drugs related information. It is managed by the Toxicology and Environmental Health Information Program (TEHIP) in the Division of Specialized Information Services (SIS) of the National Library of Medicine (NLM).". https://chem.sis.nlm.nih.gov/chemidplus/... (accessed September 17, 2018).
- EPA DSStox. "Ciprofloxacin: DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.". https://comptox.epa.gov/dashboard/dsstox... (accessed September 17, 2018).
- European Chemicals Agency - ECHA. "1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl): The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-on-ch... (accessed September 17, 2018).
- FDA/SPL Indexing Data. "5E8K9I0O4U: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/DataStan... (accessed September 17, 2018).
ReviewsThe results of a survey conducted on ndrugs.com for Ciprofloxacin 0.3% Thephaco are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ciprofloxacin 0.3% Thephaco. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
1 consumer reported dosesWhat doses of Ciprofloxacin 0.3% Thephaco drug you have used?
The drug can be in various doses. Most anti-diabetic, anti-hypertensive drugs, pain killers, or antibiotics are in different low and high doses and prescribed by the doctors depending on the severity and demand of the condition suffered by the patient. In our reports, ndrugs.com website users used these doses of Ciprofloxacin 0.3% Thephaco drug in following percentages. Very few drugs come in a fixed dose or a single dose. Common conditions, like fever, have almost the same doses, e.g., [acetaminophen, 500mg] of drug used by the patient, even though it is available in various doses.
Information checked by Dr. Sachin Kumar, MD Pharmacology